ACP
STOK icon

Acuta Capital Partners’s Stoke Therapeutics STOK Stock Holding History

Acuta Capital Partners’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-45,000
Closed -$1.75M – 49
2021
Q1 		$1.75M Sell
45,000
-47,500
-51% -$2.7M 0.63% 37
2020
Q4 		$5.73M Buy
+92,500
New +$4.24M 1.56% 26

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Acuta Capital Partners's STOK Position: Q2 2021 in Review

Acuta Capital Partners sold out of Stoke Therapeutics (STOK) in Q2 2021, closing a stake of 45,000 shares — an estimated $1.75M sold.

Acuta Capital Partners first reported a position in STOK in Q4 2020 and held it in 2 quarters. The position peaked at $5.73M in Q4 2020. 97 funds tracked by Wall St. Rank hold STOK as of Q2 2021.

  • Acuta Capital Partners reported no remaining Stoke Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Acuta Capital Partners sold 45,000 Stoke Therapeutics shares in Q2 2021, an estimated $1.75M.
  • Acuta Capital Partners first reported a position in Stoke Therapeutics in Q4 2020 and held it in 2 quarters.
  • Acuta Capital Partners's Stoke Therapeutics position peaked at $5.73M in Q4 2020.
  • 97 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2021.

Based on Acuta Capital Partners's 13F filing for Q2 2021, filed 16 Aug 2021.